文献速递抗栓抗凝管理药物不良反应与药物警戒

阿加曲班联合超声辅助导管定向溶栓治疗肝素诱导性血小板减少症合并肺栓塞

Treatment of pulmonary embolism with argatroban and ultrasound-assisted catheter-directed thrombolysis with alteplase in a patient with heparin-induced thrombocytopenia.
PubMed 文献 · Am J Health Syst Pharm · 2017-01-01

本文报告一例76岁女性心脏术后双侧肺栓塞合并肝素诱导性血小板减少症(HIT)的病例。患者因近期肝素暴露疑诊HIT而换用阿加曲班,第9天出现呼吸困难加重且血栓负荷增加,第12天接受阿加曲班联合低剂量阿替普酶的超声辅助导管定向溶栓(USAT)治疗,约20小时后拔管,血流动力学明显改善、双侧肺动脉压下降,后转为华法林并于第19天出院。

要点

  • HIT合并肺栓塞且存在右心室功能不全时,可考虑导管定向治疗。
  • 本例采用阿加曲班联合低剂量阿替普酶USAT,约20小时后拔除导管和鞘管。
  • 治疗后血流动力学明显改善、双侧肺动脉压下降,最终过渡为华法林并出院。

核心结论

  • HIT合并双侧肺栓塞患者采用阿加曲班联合阿替普酶USAT治疗获得成功。

研究设计与样本

  • 个案报告:一例76岁白人女性,近期接受心脏手术,因双侧肺栓塞入院。

主要发现

  • 患者疑诊HIT后由普通肝素换为阿加曲班,临床好转,第7天换用利伐沙班。
  • 第9天呼吸困难加重,CT血管造影示血栓负荷增加。
  • 第12天行阿替普酶联合阿加曲班的USAT(EkoSonic系统),约20小时后拔除导管和鞘管。
  • 治疗后血流动力学明显改善,双侧肺动脉压下降。
  • 患者转为华法林治疗,第19天出院。

临床怎么用

  • 对HIT合并肺栓塞、存在右心室功能不全且系统抗凝可能不足者,可考虑阿加曲班联合导管定向溶栓。
  • 围术期需关注导管和鞘管的拔除时机及抗凝方案转换。

局限性

  • 为单例个案报告,无法据此推广疗效与安全性结论。
  • 原文指出HIT背景下导管定向溶栓联合非肝素抗凝、尤其肺栓塞相关的文献有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Successful ultrasound-assisted catheter-directed thrombolysis (USAT) with low-dose alteplase and argatroban in a patient with bilateral pulmonary embolism (PE) secondary to heparin-induced thrombocytopenia (HIT) is reported. SUMMARY: HIT is a life-threatening complication associated with a high risk of thromboembolism. Systemic anticoagulation for the treatment of thrombosis may not be sufficient in the presence of PE. Catheter-directed treatment may be indicated in patients with PE and associated right ventricular dysfunction. Literature describing the use of nonheparin anticoagulation with catheter-directed thrombolysis in the setting of HIT, particularly in the context of PE, is limited. A 76-year-old Caucasian woman with recent cardiac surgery was hospitalized with bilateral PE. Unfractionated heparin was initiated, but the patient was switched to argatroban upon suspicion of HIT due to recent heparin exposure. The patient clinically improved and was switched to rivaroxaban on hospital day 7 for long-term anticoagulation. She developed worsening dyspnea on hospital day 9, and a computed tomography angiogram revealed an increased clot burden. On hospital day 12, the patient underwent USAT with alteplase and argatroban using the EkoSonic Endovascular System (EKOS Corporation, Bothell, WA). The catheters and sheaths were removed after approximately 20 hours, and the patient had marked hemodynamic improvement with reduced bilateral pulmonary arterial pressure. She was transitioned to warfarin therapy and discharged on hospital day 19. CONCLUSION: A woman with HIT and bilateral PE was successfully treated with the combination of argatroban and USAT with alteplase.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Bethea BT, Elliot JW, Richardson JB, et al. Treatment of pulmonary embolism with argatroban and ultrasound-assisted catheter-directed thrombolysis with alteplase in a patient with heparin-induced thrombocytopenia. Am J Health Syst Pharm. 2017. PMID: 28743779. doi:10.2146/ajhp160368

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。